Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

Jørgen Rungby

doi:10.1517/13543780902953707

Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

Jørgen Rungby

Endokrinologisk Afdeling BFH

6 Citationer (Scopus)

Abstract

BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.

Originalsprog	Engelsk
Tidsskrift	Expert Opinion on Investigational Drugs
Vol/bind	18
Udgave nummer	6
Sider (fra-til)	835-838
Antal sider	4
ISSN	1354-3784
DOI	https://doi.org/10.1517/13543780902953707
Status	Udgivet - 2009

Adgang til dokumentet

10.1517/13543780902953707

Citationsformater

@article{99057a5e67ab4c9f8d320d50b2daadcf,

title = "Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes",

abstract = "BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.",

keywords = "Animals, Antigens, CD26, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drugs, Investigational, Glucagon-Like Peptide 1, Humans, Insulin-Secreting Cells, Molecular Structure, Purines, Quinazolines",

author = "J{\o}rgen Rungby",

year = "2009",

doi = "10.1517/13543780902953707",

language = "English",

volume = "18",

pages = "835--838",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

AU - Rungby, Jørgen

PY - 2009

Y1 - 2009

N2 - BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.

AB - BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.

KW - Animals

KW - Antigens, CD26

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 2

KW - Drugs, Investigational

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Insulin-Secreting Cells

KW - Molecular Structure

KW - Purines

KW - Quinazolines

U2 - 10.1517/13543780902953707

DO - 10.1517/13543780902953707

M3 - Journal article

SN - 1354-3784

VL - 18

SP - 835

EP - 838

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 6

ER -

Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater